Global distribution of invasive serotype 35D streptococcus pneumoniae isolates following introduction of 13-valent pneumococcal conjugate vaccine

Stephanie W. Lo, Rebecca A. Gladstone, Andries J. Van Tonder, Paulina A. Hawkins, Brenda Kwambana-Adams, Jennifer E. Cornick, Shabir A. Madhi, Susan A. Nzenze, Mignon Du Plessis, Rama Kandasamy, Philip E. Carter, Özgen Köseoglu Eser, Pak Leung Ho, Naima Elmdaghri, Sadia Shakoor, Stuart C. Clarke, Martin Antonio, Dean B. Everett, Anne Von Gottberg, Keith P. KlugmanLesley McGee, Robert F. Breiman, Stephen D. Bentley

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)


A newly recognized pneumococcal serotype, 35D, which differs from the 35B polysaccharide in structure and serology by not binding to factor serum 35a, was recently reported. The genetic basis for this distinctive serology is due to the presence of an inactivating mutation in wciG, which encodes an O-acetyltransferase responsible for O-acetylation of a galactofuranose. Here, we assessed the genomic data of a worldwide pneumococcal collection to identify serotype 35D isolates and understand their geographical distribution, genetic background, and invasiveness potential. Of 21,980 pneumococcal isolates, 444 were originally typed as se-rotype 35B by PneumoCaT. Analysis of the wciG gene revealed 23 isolates from carriage (n= 4) and disease (n= 19) with partial or complete loss-of-function mutations, including mutations resulting in premature stop codons (n= 22) and an inframe mutation (n= 1). These were selected for further analysis. The putative 35D isolates were geographically widespread, and 65.2% (15/23) of them was recovered after the introduction of pneumococcal conjugate vaccine 13 (PCV13). Compared with serotype 35B isolates, putative serotype 35D isolates have higher invasive disease potentials based on odds ratios (OR) (11.58; 95% confidence interval[CI], 1.42 to 94.19 versus 0.61; 95% CI, 0.40 to 0.92) and a higher prevalence of macrolide resistance mediated by mefA (26.1% versus 7.6%; P= 0.009). Using the Quellung reaction, 50% (10/20) of viable isolates were identified as serotype 35D, 25% (5/20) as serotype 35B, and 25% (5/20) as a mixture of 35B/35D. The discrepancy between phenotype and genotype requires further investigation. These findings illustrated a global distribution of an invasive serotype, 35D, among young children post-PCV13 introduction and underlined the invasive potential conferred by the loss of Oacetylation in the pneumococcal capsule.

Original languageEnglish
JournalJournal of Clinical Microbiology
Issue number7
Publication statusPublished - Jul 2018


  • 35D
  • Novel serotype
  • PCV
  • Whole-genome sequencing


Dive into the research topics of 'Global distribution of invasive serotype 35D streptococcus pneumoniae isolates following introduction of 13-valent pneumococcal conjugate vaccine'. Together they form a unique fingerprint.

Cite this